ArticleAmerican journal of physiology. Cell physiology2025
Fibronectin-dependent integrin signaling drives EphA2 expression in vascular smooth muscle cells.
Abstract read
In one paragraph
Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell-Surface Signatures and Targets of Modulated Vascular Smooth Muscle Cells in Atherosclerosis: From State Identification to Precision Intervention.Journal of cardiovascular development and disease · 2026Review
- Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Brenna Pearson-GallionDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.ORCID 0000-0001-9335-119X
Alexandra C FinneyDepartment of Cellular Biology and Anatomy, LSU Health Shreveport, Shreveport, Louisiana, United States.
Matthew L ScottDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Zachary ConnellyDepartment of Urology, University of South Florida, Tampa, Florida, United States.
Shafiul AlamDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.ORCID 0000-0001-8684-624X
Jonette M PeretikDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Cyrine Ben DhaouDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Md Shenuarin BhuiyanDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.ORCID 0000-0003-0073-3071
James G TraylorDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.ORCID 0000-0002-7119-6333
William F DeGradoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States.
Hyunil JoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States.ORCID 0000-0002-4863-0779
Xiuping YuDepartment of Biochemistry and Molecular Biology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Oren RomDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Christopher B PattilloDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Nirav DhaneshaDepartment of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
Arif YurdagulDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.
A Wayne OrrDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, Louisiana, United States.ORCID 0000-0002-2377-213X
Funding
Stress Exacerbates Myocardial Ischemic Injury by Blocking Estrogen's Antidoxidant Protection in the Female HeartP20GM121307 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Anthony Wayne Orr · 2018 to 2026
$23.6MNck Adaptor Proteins in Atherogenic Endothelial ActivationR01HL133497 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2016 to 2024
$3.8MSigmar1 in lipid metabolismR01HL145753 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2019 to 2023
$2.6MDysregulations in Polyamine Metabolism During AtherosclerosisR01HL167758 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Arif Yurdagul · 2023 to 2026
$2.2MMechanisms for Deep Vein Thrombosis following StrokeR01HL158546 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Nirav Dhanesha · 2022 to 2026
$2.2MEphA2 regulation of atherosclerotic smooth muscle phenotypeR01HL173972 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Anthony Wayne Orr · 2024 to 2026
$2.1MLipidated Amino Acids in Cardiometabolic DiseasesR01DK134011 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2022 to 2026
$2.1MNovel mitophagy regulatory mechanism in heart failureR01HL172970 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Md. Shenuarin Bhuiyan · 2024 to 2026
$2.0MCellular Reductive State Regulates ArteriogenesisR01HL139755 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI PATTILLO, CHRISTOPHER BRUCE · 2019 to 2023
$1.8MEphA2 signaling in atherosclerotic fibroproliferative remodelingR01HL141155 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2019 to 2022
$1.8MDysregulated Oxalate Metabolism in Cardiometabolic DiseasesR01DK136685 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2023 to 2026
$1.7MAndrogen Deprivation Activates Wnt/Beta-Catenin Signaling in Prostate CancerR01CA226285 · NCI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI YU, XIUPING · 2018 to 2022
$1.6MAmerican Heart Association (AHA) 13GRNT17050093American Heart Association (AHA) 17PRE33440111American Heart Association (AHA) 18POST34080495American Heart Association (AHA) 20POST35220022American Heart Association-American Stroke Association 18POST34080495Carrol FeistCenter for Cardiovascular Diseases and SciencesHHS | NIH | National Cancer Institute (NCI) CA226285HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL133497HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL139755HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL141155HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL145131HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL145753HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL145753-01S1HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL145753-03S1HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL150233HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL158546HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL167758HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL172970HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL17397HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK131859HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK134011HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK136685LSU | LSUS | LSU Health Shreveport (Louisiana Health Shreveport, Louisiana State University Shreveport)Malcolm FeistNCI NIH HHS R01 CA226285NHLBI NIH HHS K99 HL150233NHLBI NIH HHS R00 HL145131NHLBI NIH HHS R00 HL150233NHLBI NIH HHS R01 HL133497NHLBI NIH HHS R01 HL139755NHLBI NIH HHS R01 HL141155NHLBI NIH HHS R01 HL145753NHLBI NIH HHS R01 HL158546NHLBI NIH HHS R01 HL167758NHLBI NIH HHS R01 HL172970NHLBI NIH HHS R01 HL173972NIDDK NIH HHS F31 DK131859NIDDK NIH HHS R01 DK134011NIDDK NIH HHS R01 DK136685NIGMS NIH HHS P20 GM121307
Abstract
Vascular smooth muscle cells undergo a phenotypic shift to a "synthetic" phenotype during atherosclerosis characterized by downregulation of contractile markers and augmented proliferation, migration, and extracellular matrix deposition. While absent in contractile smooth muscle cells, the receptor tyrosine kinase EphA2 shows enhanced expression in synthetic vascular smooth muscle in vitro and in atherosclerotic plaques in vivo. EphA2 deletion in atheroprone
Indexed as
AtherosclerosisFibronectinsIntegrinsMuscle, Smooth, VascularMyocytes, Smooth MuscleReceptor, EphA2AnimalsApolipoproteins ECell AdhesionCells, CulturedExtracellular MatrixHumansMaleMiceMice, Inbred C57BLMice, KnockoutApolipoproteins EEPHA2 protein, humanFibronectinsIntegrinsNF-kappa BReceptor, EphA2EphA2fibronectinintegrinsNF-κBvascular smooth muscle
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.